Canaccord lowered the firm’s price target on Passage Bio (PASG) to $67 from $260 and keeps a Buy rating on the shares. The firm decreased its peak penetration and probability of success assumptions given the evolving competitive landscape and to await more details on the safety profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG: